Protagonist Therapeutics Hits New 52-Week High of $65.08

Protagonist Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 65.08 on September 23, 2025. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 96.14%, significantly outpacing the S&P 500's growth of 17.38% during the same period.
The company's market capitalization stands at USD 3,496 million, reflecting its position within the small-cap segment. Protagonist Therapeutics has a price-to-earnings (P/E) ratio of 60.00, indicating investor expectations for future growth. Additionally, the company maintains a return on equity of 7.79%, showcasing its ability to generate profits from shareholders' equity.

Despite a debt-to-equity ratio of -0.85, which suggests a strong balance sheet, the company does not currently offer a dividend yield. The price-to-book ratio of 5.23 further highlights the valuation metrics that investors are considering as they assess Protagonist Therapeutics' performance in the competitive biotechnology landscape.